Division 1 Identification of the product
United Kingdom
An identification of the veterinary medicinal product(s) used in the testing shall be provided, including:
-
composition,
-
the physical and chemical (potency and purity) test results for the relevant batch(es),
-
batch identification,
-
relationship to the final product,
-
specific activity and radio-purity of labelled substances,
-
position of labelled atoms in the molecule.
The dossier of residue tests shall include:
-
an index of all studies included in the dossier,
-
a statement confirming that all data known by the applicant at the time of submission, whether favourable or unfavourable, are included,
-
a justification for the omission of any type of study,
-
an explanation of the inclusion of an alternative type of study,
-
a discussion of the contribution that any study that pre-dates GLP can make to the overall risk assessment,
-
a withdrawal period proposal.
Each study report shall include:
-
a copy of the study plan (protocol),
-
a statement of compliance with good laboratory practice, where applicable,
-
a description of the methods, apparatus and materials used,
-
a description of the results obtained, in sufficient detail to allow the results to be critically evaluated independently of their interpretation by the author,
-
a statistical analysis of the results where appropriate,
-
a discussion of the results,
-
an objective discussion of the results obtained, and proposals concerning the withdrawal periods necessary to ensure that no residues which might constitute a hazard for consumers are present in foodstuffs obtained from treated animals.
Notes on Annex II
Footnotes
- f1
-
This Annex will be amended by the Commission in accordance with Articles 146 and 153. All references to Articles or to ‘this Directive’ in this Annex, unless otherwise specified, are to be understood as references to Directive 2001/82/EC.